CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicing the effect of GHRH).  It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this.It stimulates production of our own growth hormone from the pituitary gland.  
In June 2007, the NDPSC decided to extend the exemption from the limit on paracetamol combinations being allowed as general sale products to include phenylephrine (as long as it also qualified as exempt from scheduling through the phenylephrine entries). At that time, the NDPSC considered that the safety profile of these substances was such that allowing a fixed combination to be unscheduled was reasonable.
GHRPs are not simply surrogates of GHRH, instead GHRP-6 is an artificial activator of a separate newly discovered receptor called Growth Hormone Secretagogue Receptor (GHS-R). Soon Ghrelin was discovered, the endogenous ligand that binds to the GHS-R. Both Ghrelin and all the synthetic compounds such as GHRP-6 were termed "Growth Hormone Secretagogues" (GHSs). One side effect of GHRP-6 is a significant increase in appetite due to stimulating the release of Ghrelin, a peptide that is released naturally in the lining of the stomach that increases hunger and gastric emptying. Also, GHRP-6 causes stimulation of the anterior pituitary gland which causes an increase in Growth Hormone release. The increased amounts of Growth Hormone can cause the liver to secrete the hormone IGF-1, which improves the animal body’s ability to burn fat and build muscle. Since GHRP-6 acts directly on the feedback loop which signals the inhibition of Growth Hormone release, GHRP-6 can re-stimulate the production of Growth Hormone.
CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.
Our first human GHRP-6 studies in normal young men were performed in collaboration with Michael Thorner (Bowers et al., 1990). These studies (Fig. 1.7, left panel) revealed that iv bolus GHRP-6 released GH and, when given together with GHRH, released GH synergistically. One of the most characteristic and consistent in vivo actions of GHRPs in various animals as well as humans of both sexes and all ages is the synergistic release of GH when GHRP is administered concomitantly with GHRH by iv bolus. Subsequently, this was also found for continuous 24/7 subcutaneous (sc) infusion. Also recorded in Fig. 1.7, right panel, is the comparative GH-releasing effects of iv bolus GHRP-6, -1, -2, and GHRH in normal young men. The potency of the three GHRPs we developed over several years was increasingly effective in releasing GH, and each released more GH than GHRH in normal young men. In addition, this was also found to occur in normal young women (Bowers, 1996).
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy.  Some of these issues can be caused by adult growth hormone deficiency.  Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.

Two submissions supported the proposal as advertising was considered to bring important benefits in terms of better information for consumers on the availability of a combination product with rapid and effective pain relief and reduced doses of analgesic. Responsible advertising will alert consumers that combination products are available from pharmacies with advice from the pharmacist. One submission opposed the proposal as it was believed that there would be no benefit to the consumer by amending Appendix H to include a new entry for paracetamol/ibuprofen.


The number of infiltrating immunoinflammatory cells and neoformed vessels was determined within the granulation tissue of each wound. For this purpose, images of at least 10 microscopic fields (10–20x magnification) were captured and photographed so that mature vascular structures and infiltrated mononuclear cells were counted along with the assistance of the ImageJ processing system, version 1.46r.
Peptide therapy, or the use of specific peptides in treatment, has gained great popularity in recent years. This is due largely to the fact that these peptides are highly specific (i.e., only do what you want them to do) while also being well-tolerated and safe. As of January 2015, there were over 60 US FDA-approved peptide medications, 140 peptide drugs being evaluated in clinical trials, and 500 in pre-clinical development.
In 2005, we undertook a porcine model of AMI via left circumflex artery occlusion for 1 hour followed by a 72-hour reperfusion period. GHRP-6 rescued ischemic myocardium from death for over 70% of the area at risk (Figure 3), and that in addition to enhance survival signaling pathways/gene expression of the PI-3K, AKT1, and BCL2 pathways, GHRP-6 decreased reactive oxygen species (ROS) spillover, the inflammatory marker CRP, and preserved the antioxidant defenses.45 These antioxidant and anti-inflammatory properties have also been attributed to GHRP-2 when its antiatherogenic potential was examined in ApoE(−/−) mice so that 12/15-lipoxygenase, interferon gamma, and macrophage migration inhibitory factor (MMF) gene expression were accounted. Furthermore, in cultured aortic smooth muscle cells, GHRP-2 prevented the generation of peroxides, the downregulation of IGF-1 receptor, and the commitment of apoptosis.46

Thymosin beta 4 (Tβ4) is the predominant form of thymosin in our bodies. It has been found in high concentrations in wound tissue and certain blood cells involved in clotting, signifying its important role in the healing process. In fact, recent studies have revealed that the first gene to be upregulated after an injury is the Tβ4 gene. As the body begins the recovery process, Tβ4 aids in the creation of new vessels in the injured area, which carry blood, nutrients, and reparative substances to the site. Tβ4 also has anti-inflammatory properties, and works to decrease the amount of inflammatory substances, called cytokines. Inflammation plays a large role in many of the symptoms associated with a large number of conditions (i.e., Lyme disease, CFS, FM, autoimmune diseases, infections, etc.), making the potential impact of Tβ4 quite extensive.


As we mentioned above, the results you are going to realize are different for each user. An athlete might see immediate and greater gains, than a 50-year old male who has never stepped foot in a gym and is 30 pounds overweight. So, make sure you bear this in mind as you are determining whether or not Ipamorelin is right for you. Further, if incorporating other supplements like CJC 1295 or additional growth hormones, the results are also going to be greater than if you are simply using Ipamorelin on its own. Make sure you are aware of this, and how to properly incorporate it with other supplements, in order to ensure the best possible results with use.
However, after the administration, Mod GRF 1-29 starts breaking down soon. This happens because peptides have a strong affinity for bonding with amino acids. The administered peptide has to travel a long distance between the point of administration and the pituitary gland. On the way, the enzymes act on it making it break down and bond with the amino acids. The peptides that are secreted by the body on its own do not have to face this problem because they do not have to travel this long.
TGA evaluator concluded that the consistent absence of any clinically meaningful effects on blood pressure (BP) or heart rate (HR) in the applicant's bioavailability studies, and the absence of any ADR reports of BP, HR or other cardiovascular problems, indicate that "there is no valid reason for concern and no need to take any regulatory against the combination products currently in the ARTG and available in the Australian market", i.e. no demonstrated safety risk, and no evidence provided of efficacy of paracetamol 1000 mg / phenylephrine HCl 5 mg adult dose.
In extracardiac models of striated muscles atrophy, GHRP-2 exerted a potent myoprotective effect, presumably via the direct agonistic stimulation of the GHS-R1a since no elevation of IGF-1 transcript was observed.49 Thus, it is likely that GHRP cardioprotective effects in scenarios of DCM may be somehow mediated by a trophic or anabolic mechanism. Based on the benefits of GHRP-6 on muscle functions, a newly synthesized GHRP-6-biotin conjugate tested on cultured myoblasts showed that it induced the expression of myogenic proteins and IGF-1 levels similar to the concentrations of energy metabolites and the corresponding enzymes. Practical applications of the GHRP-6-biotin conjugate could include amelioration of sarcopenia and/or cardiac cachexia.50
When you are just getting started with Ipamorelin, it is advised to use only one supplement daily at the same time each day. It is also advised to begin on the lower end, typically an eight-week cycle, and at a maximum twelve-week cycle. Doing this not only guarantees the desired results when using Ipamorelin, it is also going to ensure you get the most out of the supplement. When using this dosage cycle you will:
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.
In 1984, a synthetic hexapeptide, His-d-Trp-Ala-Trp-d-Phe-Lys-NH2 (GHRP-6), was identified by Bowers and colleagues. This hexapeptide was shown to potently stimulate GH release in vitro and in vivo by an unknown mechanism. Because of its poor oral bioavailability (0.3%) and short half-life (20 min) in human serum, GHRP-6 was selected only as a structural model to design a nonpeptide mimetic. Based on the structure–activity relationships (SARs) of GHRP-6, the nonpeptidyl growth hormone secretagogue (GHS) L-692,429 was identified by Smith et al. in 1993. This nonpeptidyl GHS synergizes with GHRP-6 to stimulate GH release and cAMP production, accompanied by a significant increase in intracellular calcium concentration ([Ca2 +]i), indicating that this nonpeptidyl GHS acts through a distinct signal transduction pathway. In 1995, a potent oral GHS L-163,191 (MK-0677) was reported by Patchett et al. This agent was found to have excellent oral bioavailability and specificity in its release of GH, without significant effect on plasma levels of other hormones such as aldosterone, luteinizing hormone, thyroxine, and prolactin.
Peptides: Are a small chain of amino acids that isn’t quite long enough to be considered a protein. In other words they are the building blocks for protein in the body. They actually have a wide range of functions with the most popular being an increase in growth hormone, increase in recovery (and by default muscle building) and even a natural tan.
ADV Research ADV-516 30mgs/ml Will de dispatched Friday 15th June – Pre Orders Now KEY BENEFITS Speed up fat burning by enhancing your fatty acid metabolism Trigger the same genetic paths as using energy during exercise Supercharge your strength, energy, and endurance Hold onto muscle tissue while dieting – non-catabolic Store less carbs and fat as adipose tissue Grow a…
The importance of limiting myocardial ischemia/reperfusion injury has been appreciated since Braunwald23,24 proposed that the extent and severity of tissue damage were not predetermined at the onset of ischemia, but could be modified by therapeutic manipulations applied during ischemia. Few years ago, a National Institutes of Health (NIH) expert’s panel concluded that cardioprotection is at a crossroads since approaches to identify cardioprotective therapies have been disappointing during the past 30 years.25 This may be related to the fact that the multiple candidates assayed so far target one single pathogenic event of the multiple damage cascade involved in myocardial damage and failure.25
 Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.
CJC 1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC 1295 shown potential to increase growth hormone and IGF-I secretion and effects, but it has been able to do so in very large amounts. CJC 1295 Stimulates Growth Hormone Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis thereby promoting growth.
The most important initial historical time points in the development of the enlarging ghrelin system were 1973, 1976, 1982, 1984, 1990, 1996, 1998, and 1999 during which the following sequentially occurred: isolation of somatostatin; discovery of unnatural growth-hormone-releasing peptides (GHRPs); isolation of growth-hormone-releasing hormone (GHRH); hypothesis of a new natural GHRP different from GHRH; GHRP+GHRH synergism in humans; discovery of the growth hormone secretagogue GHS/GHRP receptor; cloning of the receptor; isolation; and identification of the new natural endogenous GHRP ghrelin.1
As the name indicates, this peptide is a fragment of human growth hormone. It is more specifically a modified form of the amino acids 176-191 in the C-terminal section of the latter substance. Bodybuilders mainly use it enhance fat burning for improved and more noticeable muscle growth. For weight loss, HGH Fragment 176-191 is thought to be considerably more potent than regular growth hormone. It also offers anti-aging benefits as a result of positive effects on IGF-1 levels.

Peptides offer a number of health benefits and bodybuilding is a field where these peptides are useful as well. When it comes to bodybuilding and sports performance, peptides help increase number of muscle cells. They even help to reverse the generic outlook along with allowing you to increase the muscle density. Use of peptides simply means that you will be able to develop muscle density you dream of.


Our first human GHRP-6 studies in normal young men were performed in collaboration with Michael Thorner (Bowers et al., 1990). These studies (Fig. 1.7, left panel) revealed that iv bolus GHRP-6 released GH and, when given together with GHRH, released GH synergistically. One of the most characteristic and consistent in vivo actions of GHRPs in various animals as well as humans of both sexes and all ages is the synergistic release of GH when GHRP is administered concomitantly with GHRH by iv bolus. Subsequently, this was also found for continuous 24/7 subcutaneous (sc) infusion. Also recorded in Fig. 1.7, right panel, is the comparative GH-releasing effects of iv bolus GHRP-6, -1, -2, and GHRH in normal young men. The potency of the three GHRPs we developed over several years was increasingly effective in releasing GH, and each released more GH than GHRH in normal young men. In addition, this was also found to occur in normal young women (Bowers, 1996).

IGF-1 also increases the activity of muscle protein synthesis and the activity of muscle stem cells (also called satellite cells) for repair of damaged muscle. This is probably why intense weight training is one primary stimulus for a natural release of IGF-1 in muscle. As a matter of fact, exercise researchers have found that systemic IGF-1 normally produced in the liver isn’t even required for this type of muscle repair, as other IGF-1 forms produced by your own muscles during and post-exercise allows for adequate muscle tissue repair.
There is evidence of involvement of organised crime in supply of the substances. The substances are offered for sale via the internet. Many of the substances are promoted as safe alternatives to traditional performance enhancing substances such as the anabolic steroids. Suppliers are making unproven assertions about the efficacy and safety of the substances.
By increasing our own growth hormone levels (which normally decrease as we age), there is an increase in protein synthesis which subsequently stimulates muscle growth.  It leads to an increase in muscle mass, an increase in fat metabolism (fat loss), and increase in physical strength.  It is also helpful in skin ageing, and effective in reducing wrinkles.
It is here that Growth Hormone Releasing Peptide 6, or Growth Hormone Releasing Hexapeptide comes into the picture. Also called as GHRP-6, it is a synthetic met-enkephalin analog. It includes unnatural D amino acids. It is instrumental in releasing growth hormone that helps in muscle recovery, strengthing of joints and tendons, and fat loss. It is distinct from Growth Hormone Releasing Hormone or GHRH which causes a higher amount of growth hormone to be secreted during the body normal secretion time. GHRP-6 on the other time will target a pulse and force the pituitary to release the growth hormone that is stored there. It helps a particular muscle group to achieve maximum growth.
CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.
Unlike GHRP 6, the Half Life of GHRP 2 is pretty short. In fact, GHRP 2’s peak can be seen occurring within fifteen minutes after it has been administered or at least one hour at the latest. Also unlike GHRP 6, GHRP 2 helps improve the levels of calcium in the body and this can in turn facilitate the secretion of other growth hormones. GHRP 2 is believed to be more potent in its operation as compared to other peptide forms, including GHRP 6. Therefore, it is not surprising to see this peptide commonly employed for treating catabolic deficiencies.
×